travoprost

Trade name: travatan

Small moleculeapproved

Approved

Mar 16, 2001

Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor. Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility. Travoprost ophthalmic solution is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. Travoprost is known by the brand names of Travatan and Travatan Z, manufactured by Alcon. — NCATS

Clinical trial activity

133 trials · 49 clinical orgs · 15 marketing orgs

Phase 1
3
Phase 2
54
Phase 3
37
Phase 4
66

Earliest trial started Jan 1, 2000 (NCT00051181)

Timeline

2000s

  1. Jan 1, 2000

    Alcon — Earliest Phase 3 Sponsor(trial)

  2. Mar 16, 2001

    Alcon — Earliest FDA Approval

  3. Mar 16, 2001

    Alcon — NDA Organization

  4. Mar 16, 2001

    Nestle — NDA Secondary Org

  5. Sep 21, 2006

    Novartis — NDA Secondary Org

  6. Sep 21, 2006

    Novartis — Marketing Organization

  7. Sep 21, 2006

    Sandoz — Marketing Organization

  8. Jan 1, 2007

    Alcon — Earliest Phase 2 Sponsor(trial)

2010s

  1. Aug 19, 2011

    Par Pharmaceuticals — Marketing Organization

  2. Jan 1, 2013

    Alcon — Earliest Phase 1 Sponsor(trial)

  3. Mar 1, 2013

    Strides Pharma Science — Marketing Organization

  4. Mar 1, 2013

    Chartwell Pharmaceuticals — Marketing Organization

  5. Jul 10, 2015

    Apotex — Marketing Organization

  6. Jul 7, 2017

    Mylan — Marketing Organization

  7. Dec 20, 2019

    Alembic — Marketing Organization

2020s

  1. Mar 19, 2021

    Micro Labs Ltd India — Marketing Organization

  2. Dec 13, 2023

    Glaukos Corporation — Marketing Organization

  3. May 3, 2024

    Lupin — Marketing Organization

  4. Jul 12, 2024

    Gland Pharma Ltd — Marketing Organization

  5. Sep 23, 2024

    Somerset Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewMar 16, 2001

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC2=CC(=CC=C2)C(F)(F)F
Mol. weight
500.5477 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Prodrug

Sources

Also known as

  • al-6221
  • al-6221
  • isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
  • isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
  • izba
  • izba
  • izba
  • izba
  • izba
  • izba
  • travaprost
  • travatan
  • travatan
  • travatan
  • travatan
  • travatan
  • travatanz
  • travatan z
  • travatan z
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost
  • travoprost / timolol
  • travoprostum
  • travoprostum

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07228221Phase 4Jan 5, 2026Glaukos Corporation, Thomas Jefferson University
NCT06848946Phase 4Jan 13, 2025Glaukos Corporation
NCT06152861Phase 2Nov 15, 2023Glaukos Corporation
NCT06066645Phase 3Sep 14, 2023Glaukos Corporation
NCT06061718Phase 3Sep 11, 2023Glaukos Corporation
NCT05335122Phase 2Mar 16, 2022Ocular Therapeutix, Inc.
NCT04962009N/ASep 8, 2021Mati Therapeutics Inc.
NCT06582732Phase 2Mar 10, 2021Glaukos Corporation
NCT04577027Phase 4Jan 1, 2021Assiut University
NCT04615403Phase 2Nov 30, 2020Glaukos Corporation
NCT04868175N/AOct 1, 2019The University of Hong Kong
NCT03965052Phase 1Apr 23, 2019Laboratorios Sophia S.A de C.V.
NCT03868124Phase 3Aug 2, 2018Glaukos Corporation
NCT04061044Phase 3Jul 10, 2018Ocular Therapeutix, Inc.
NCT03519386Phase 3May 31, 2018Glaukos Corporation
NCT02914509Phase 3Sep 1, 2016Ocular Therapeutix, Inc.
NCT02796560Phase 4Jul 1, 2016University of Sherbrooke
NCT02730871Phase 4Jun 17, 2016Alcon
NCT02754596Phase 2Mar 1, 2016Glaukos Corporation
NCT02419508Phase 4Aug 7, 2015Alcon
Showing 20 of 133 trials
Page 1 / 7

Organizations

Research & Development (49)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AlconFor profit736852000
Glaukos CorporationFor profit131232011
AllerganFor profit6612006
Ocular Therapeutix, Inc.For profit5532013
Aristotle University of ThessalonikiAcademic/Hospital4422006
PfizerFor profit3112002
S.V. Malayan Eye CenterAcademic/Hospital3012011
Aerie PharmaceuticalsFor profit2212011
Innovative Medical Research of South Florida, IncFor profit2212006
Singapore National Eye CentreAcademic/Hospital2112007
Thomas Jefferson UniversityAcademic/Hospital2212008
University of PittsburghAcademic/Hospital2012006
University of Sao PauloAcademic/Hospital2212005
University of SherbrookeAcademic/Hospital2222009
Afyon Kocatepe UniversityAcademic/Hospital1112014
Alan L. Robin, M.D.Academic/Hospital1012005
Arlington eye AssociatesAcademic/Hospital1012008
Assiut UniversityAcademic/Hospital1112021
Cairo UniversityAcademic/Hospital1112011
Envisia TherapeuticsFor profit1112015
49 organizations
Page 1 / 3

Marketing (21)

OrganizationOrg typeRelationshipDate
AlconFor profitNDAMar 16, 2001
AlembicFor profitMKTGDec 20, 2019
AlembicFor profitSYNDec 20, 2019
ApotexFor profitMKTGJul 10, 2015
ApotexFor profitSYNJul 10, 2015
Chartwell PharmaceuticalsFor profitMKTGMar 1, 2013
Gland Pharma LtdFor profitMKTGJul 12, 2024
Gland Pharma LtdFor profitSYNJul 12, 2024
Glaukos CorporationFor profitMKTGDec 13, 2023
LupinFor profitMKTGMay 3, 2024
LupinFor profitSYNMay 3, 2024
Micro Labs Ltd IndiaFor profitMKTGMar 19, 2021
MylanFor profitMKTGJul 7, 2017
MylanFor profitSYNJul 7, 2017
NestleFor profitNDA2Mar 16, 2001
NovartisFor profitNDA2Sep 21, 2006
NovartisFor profitMKTGSep 21, 2006
Par PharmaceuticalsFor profitMKTGAug 19, 2011
SandozFor profitMKTGSep 21, 2006
Somerset PharmaceuticalsFor profitMKTGSep 23, 2024
Strides Pharma ScienceFor profitMKTGMar 1, 2013